Aadi Bioscience (AADI) Appoints Mohammad Hirmand to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/13/2026
- Wall Street slips as Iran tensions hit sentiment; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil gains over 4% as Trump says US reinstating Iran naval blockade
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- Former emir of Qatar, Sheikh Hamad bin Khalifa Al Thani, dies at 74
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- Wall Street slips as Iran tensions hit sentiment; chipmakers drop
- Japan has no plans to overhaul pension funds' asset allocation, sources say
Aadi Bioscience Appoints Mohammad Hirmand, M.D. to Board of Directors
March 27, 2023 8:00 AM EDTLOS ANGELES, March 27, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the appointment of Mohammad Hirmand, M.D. to its Board of Directors. Dr. Hirmand has more than 20 years of biotechnology clinical... More
